{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:58Z","timestamp":1792621738204,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":318,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.mayocp.2012.06.016","type":"journal-article","created":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T14:18:17Z","timestamp":1343830697000},"page":"843-852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus"],"prefix":"10.1016","volume":"87","author":[{"given":"Irwin","family":"Goldstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeRoy A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence H.","family":"Belkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda A.","family":"Trask","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2012.06.016_bib2","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/sj.ijir.3900910","article-title":"Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus","volume":"14","author":"Vickers","year":"2002","journal-title":"Int J Impot Res"},{"issue":"1","key":"10.1016\/j.mayocp.2012.06.016_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1743-6109.2004.10106.x","article-title":"Epidemiology\/risk factors of sexual dysfunction","volume":"1","author":"Lewis","year":"2004","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.mayocp.2012.06.016_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjmed.2006.06.010","article-title":"Prevalence and risk factors for erectile dysfunction in the US","volume":"120","author":"Selvin","year":"2007","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2012.06.016_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.urology.2004.08.059","article-title":"Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both","volume":"64","author":"Giuliano","year":"2004","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.mayocp.2012.06.016_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jdiacomp.2010.03.003","article-title":"Diabetes-induced erectile dysfunction: epidemiology, pathophysiology and management","volume":"25","author":"Thorve","year":"2011","journal-title":"J Diabetes Complications"},{"issue":"23","key":"10.1016\/j.mayocp.2012.06.016_bib7","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2165\/00003495-200464230-00004","article-title":"New treatment options for erectile dysfunction in patients with diabetes mellitus","volume":"64","author":"Basu","year":"2004","journal-title":"Drugs"},{"issue":"6, suppl","key":"10.1016\/j.mayocp.2012.06.016_bib8","first-page":"S45","article-title":"Diabetes, obesity and erectile dysfunction: field overview and research priorities","volume":"182","author":"Chitaley","year":"2009","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.mayocp.2012.06.016_bib9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1743-6109.2010.02099.x","article-title":"Change of erectile function and responsiveness to phosphodiesterase type 5 inhibitors at different stages of streptozotocin-induced diabetes in rats","volume":"8","author":"Cho","year":"2011","journal-title":"J Sex Med"},{"issue":"1, pt 2","key":"10.1016\/j.mayocp.2012.06.016_bib10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1743-6109.2009.01624.x","article-title":"Anatomy, physiology, and pathophysiology of erectile dysfunction","volume":"7","author":"Gratzke","year":"2010","journal-title":"J Sex Med"},{"issue":"6","key":"10.1016\/j.mayocp.2012.06.016_bib11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1745-7262.2006.00223.x","article-title":"Pathophysiology and treatment of diabetic erectile dysfunction","volume":"8","author":"Moore","year":"2006","journal-title":"Asian J Androl"},{"issue":"2, pt 1","key":"10.1016\/j.mayocp.2012.06.016_bib12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1743-6109.2009.01587.x","article-title":"Diabetes exacerbates the functional deficiency of NO\/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries","volume":"7","author":"Angulo","year":"2010","journal-title":"J Sex Med"},{"issue":"9","key":"10.1016\/j.mayocp.2012.06.016_bib13","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/j.1743-6109.2010.01884.x","article-title":"The genetic inactivation of inducible nitric oxide synthase (iNOS) intensifies fibrosis and oxidative stress in the penile corpora cavernosa in type 1 diabetes","volume":"7","author":"Ferrini","year":"2010","journal-title":"J Sex Med"},{"issue":"11","key":"10.1016\/j.mayocp.2012.06.016_bib14","doi-asserted-by":"crossref","first-page":"991","DOI":"10.5551\/jat.9316","article-title":"Five-item version of the International Index of Erectile Function correlated with albuminuria and subclinical atherosclerosis in men with type 2 diabetes","volume":"18","author":"Fukui","year":"2011","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.mayocp.2012.06.016_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1001\/jama.1993.03510010089036","article-title":"Impotence","volume":"270","year":"1993","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2012.06.016_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.mayocp.2012.06.016_bib17","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.281.5.421","article-title":"Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial","volume":"281","author":"Rendell","year":"1999","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.mayocp.2012.06.016_bib18","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/diacare.25.12.2159","article-title":"Effects of tadalafil on erectile dysfunction in men with diabetes","volume":"25","author":"Saenz de Tejada","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mayocp.2012.06.016_bib19","article-title":"Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus","author":"Vardi","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2012.06.016_bib20","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1038\/sj.ijir.3901205","article-title":"Mechanisms of action of PDE5 inhibition in erectile dysfunction","volume":"16","author":"Corbin","year":"2004","journal-title":"Int J Impot Res"},{"issue":"10","key":"10.1016\/j.mayocp.2012.06.016_bib21","first-page":"435","article-title":"Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature","volume":"7","author":"Gresser","year":"2002","journal-title":"Eur J Med Res"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2012.06.016_bib22","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ijir.3901208","article-title":"Potency, selectivity, and consequences of nonselectivity of PDE inhibition","volume":"16","author":"Bischoff","year":"2004","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.mayocp.2012.06.016_bib23","series-title":"Viagra","year":"2010"},{"key":"10.1016\/j.mayocp.2012.06.016_bib24","series-title":"Cialis","year":"2010"},{"key":"10.1016\/j.mayocp.2012.06.016_bib25","series-title":"Levitra","year":"2011"},{"key":"10.1016\/j.mayocp.2012.06.016_bib26","first-page":"1196","article-title":"Rigiscan evaluation of TA-1790, a novel PDE5 inhibitor for the treatment of men with erectile dysfunction","volume":"316","author":"Lewis","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.mayocp.2012.06.016_bib27","series-title":"Stendra","year":"2012"},{"issue":"4","key":"10.1016\/j.mayocp.2012.06.016_bib28","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1743-6109.2011.02629.x","article-title":"A randomized double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction","volume":"9","author":"Goldstein","year":"2012","journal-title":"J Sex Med"},{"issue":"6","key":"10.1016\/j.mayocp.2012.06.016_bib29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(97)00238-0","article-title":"The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction","volume":"49","author":"Rosen","year":"1997","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.mayocp.2012.06.016_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0090-4295(03)00359-5","article-title":"Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.mayocp.2012.06.016_bib31","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1111\/j.1743-6109.2010.01882.x","article-title":"Interrelationship of sildenafil treatment effects on the physiological and psychosocial aspects of erectile dysfunction of mixed or organic etiology","volume":"7","author":"Althof","year":"2010","journal-title":"J Sex Med"},{"issue":"1, pt 2","key":"10.1016\/j.mayocp.2012.06.016_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1743-6109.2009.01627.x","article-title":"Pharmacotherapy for erectile dysfunction","volume":"7","author":"Eardley","year":"2010","journal-title":"J Sex Med"},{"issue":"9A","key":"10.1016\/j.mayocp.2012.06.016_bib33","doi-asserted-by":"crossref","first-page":"9M","DOI":"10.1016\/S0002-9149(03)00824-5","article-title":"Overview of phosphodiesterase 5 inhibition in erectile dysfunction","volume":"92","author":"Rosen","year":"2003","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.mayocp.2012.06.016_bib34","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/j.1743-6109.2009.01447.x","article-title":"2009 Update on phosphodiesterase type 5 inhibitor therapy, part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class","volume":"6","author":"Shindel","year":"2009","journal-title":"J Sex Med"},{"issue":"19","key":"10.1016\/j.mayocp.2012.06.016_bib35","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1161\/01.CIR.0000146906.42375.D3","article-title":"Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction","volume":"110","author":"Kloner","year":"2004","journal-title":"Circulation"},{"issue":"5, pt 1","key":"10.1016\/j.mayocp.2012.06.016_bib36","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/01.ju.0000142687.75577.e4","article-title":"Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men","volume":"172","author":"Kloner","year":"2004","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.mayocp.2012.06.016_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3132\/dvdr.2007.026","article-title":"Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus","volume":"4","author":"Hamilton","year":"2007","journal-title":"Diab Vasc Dis Res"},{"issue":"3","key":"10.1016\/j.mayocp.2012.06.016_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ijir.2011.14","article-title":"Association of lower urinary tract symptoms and erectile dysfunction: pathophysiological aspects and implications for clinical management","volume":"23","author":"Orabi","year":"2011","journal-title":"Int J Impot Res"},{"issue":"4","key":"10.1016\/j.mayocp.2012.06.016_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s11884-010-0067-2","article-title":"Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors","volume":"5","author":"Parsons","year":"2010","journal-title":"Curr Bladder Dysfunct Rep"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612006684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619612006684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:47:36Z","timestamp":1706003256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619612006684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0025619612006684"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.06.016","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2012.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}